NASDAQ : ACOG

Alpha Cognition Inc. — Company profile

Healthcare · Biotechnology · Canada

Last price 8.74 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 190.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Details

NameAlpha Cognition Inc.
SectorHealthcare
IndustryBiotechnology
Employees71
Founded2000
CeoMichael McFadden
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinCA02074J5017
Cusip02074J501
Cik0001655923
Sic2836

Key executives

NameTitle
Michael E. McFadden B.B.A.Chief Executive Officer and Director
Kenneth Anthony Cawkell B.A., LL.B.Founder, Consultant, Corporate Secretary and Director
Henry H. Du CPAVice President of Finance and Accounting and Interim Chief Financial Officer
Lauren D'Angelo M.B.A.Chief Operating Officer
Dr. Denis G. Kay M.Sc., Ph.D.Chief Scientific Officer
Timothy AyersHead of Compliance
Christine RevealVice President of Marketing and Commercial Strategy

Contact

Address1452 Hughes Street, Suite 200, Grapevine, Texas 76051, United States
Phone858 344 4375
Websitehttps://www.alphacognition.com